[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Correction
February 14, 2017

Omission of Data

Author Affiliations
 

Copyright 2017 American Medical Association. All Rights Reserved.

JAMA. 2017;317(6):648. doi:10.1001/jama.2017.0040

In the Original Investigation entitled “Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial”1 published in the December 20, 2016, issue of JAMA, data were omitted. The Design, Setting, and Participants section of the Abstract should have reported that “45 participants were randomized to receive pritelivir.” In the Results section of the Abstract, the relative risk during valacyclovir treatment should have been reported as “0.42.” In Table 1, the upper bound of the confidence intervals in the “HSV DNA log10 copies/mL” subsection should have been reported as “0.5,” “−0.1,” and “1.0,” respectively. The second and third row stubs in the “Clinical End Points” section should have read “Recurrence or incidence rate” and “Days with pain,” respectively. This article has been corrected online.

References
1.
Wald  A, Timmler  B, Magaret  A,  et al.  Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial.  JAMA. 2016;316(23):2495-2503.PubMedGoogle ScholarCrossref
×